Director TitleAgeSince
Director/Board Member 75 30/09/2013
Director/Board Member - 08/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/22 Sell

Director

131,879 0.2369%
22/11/22
OrbiMed Advisors Private Equity
SellCompany 10,280,947 18.4680%
22/11/22
OrbiMed Advisors Private Equity
SellCompany 10,280,947 18.4680%
Change 5-day change 1-year change 3-year change Capi.($)
-99.90%-99.92% - - 580
+1.15%-2.81%+55.79%+71.12% 66.37B
+0.98%-1.46%+9.38%+91.39% 58.86B
+1.07%+0.96%+26.61%+87.57% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.10%-1.49%+83.09%+58.02% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -10.31%-2.29%+35.40%+172.64% 45B
Weighted average by Cap. -0.10%-2.18%+35.14%+147.22%
Logo Tricida, Inc.
Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
Employees
57
  1. Stock Market
  2. Stocks
  3. TCDA Stock